There Are No Useful Monoclonal Antibody Treatments Left Against New COVID Variants
MONDAY, Dec. 5, 2022 (HealthDay News) -- The last of six COVID monoclonal antibody treatments has lost its federal authorization because, like the others, it no longer works against the newest Omicron subvariants.
This last monoclonal antibody was bebtelovimab, delivered as a one-hour IV infusion.
The FDA said in a statement announcing the authorization withdrawal that the drug was "not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1."
Those subvariants are now responsible for nearly 62% of new infections in the United States, according to the U.S. Centers for Disease Control and Prevention.Full Article